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Abstract
Background: Coronary artery disease (CAD), and one of its intermediate risk factors, dyslipidemia, possess a
demonstrable genetic component, although the genetic architecture is incompletely defined. We previously
reported a linkage peak on chromosome 5q31-33 for early-onset CAD where the strength of evidence for linkage
was increased in families with higher mean low density lipoprotein-cholesterol (LDL-C). Therefore, we sought to
fine-map the peak using association mapping of LDL-C as an intermediate disease-related trait to further define the
etiology of this linkage peak. The study populations consisted of 1908 individuals from the CATHGEN biorepository
of patients undergoing cardiac catheterization; 254 families (N = 827 individuals) from the GENECARD familial study
of early-onset CAD; and 162 aorta samples harvested from deceased donors. Linkage disequilibrium-tagged SNPs
were selected with an average of one SNP per 20 kb for 126.6-160.2 MB (region of highest linkage) and less dense
spacing (one SNP per 50 kb) for the flanking regions (117.7-126.6 and 160.2-167.5 MB) and genotyped on all
samples using a custom Illumina array. Association analysis of each SNP with LDL-C was performed using
multivariable linear regression (CATHGEN) and the quantitative trait transmission disequilibrium test (QTDT;
GENECARD). SNPs associated with the intermediate quantitative trait, LDL-C, were then assessed for association
with CAD (i.e., a qualitative phenotype) using linkage and association in the presence of linkage (APL; GENECARD)
and logistic regression (CATHGEN and aortas).
Results: We identified four genes with SNPs that showed the strongest and most consistent associations with LDL-
C and CAD: EBF1, PPP2R2B, SPOCK1, and PRELID2. The most significant results for association of SNPs with LDL-C
were: EBF1, rs6865969, p = 0.01; PPP2R2B, rs2125443, p = 0.005; SPOCK1, rs17600115, p = 0.003; and PRELID2,
rs10074645, p = 0.0002). The most significant results for CAD were EBF1, rs6865969, p = 0.007; PPP2R2B, rs7736604,
p = 0.0003; SPOCK1, rs17170899, p = 0.004; and PRELID2, rs7713855, p = 0.003.
Conclusion: Using an intermediate disease-related quantitative trait of LDL-C we have identified four novel CAD
genes, EBF1, PRELID2, SPOCK1, and PPP2R2B. These four genes should be further examined in future functional
studies as candidate susceptibility loci for cardiovascular disease mediated through LDL-cholesterol pathways.
Keywords: Cardiovascular Disease, Positional Cloning, Intermediate Phenotype, Linkage, Fine Mapping
* Correspondence: svati.shah@dm.duke.edu
1Center for Human Genetics, Duke University, 905 S. LaSalle Street, Duke
Univeristy Medical Center, Durham NC, 27710, USA
Full list of author information is available at the end of the article
Nolan et al. BMC Genetics 2012, 13:12
http://www.biomedcentral.com/1471-2156/13/12
© 2012 Nolan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Coronary artery disease (CAD) is the end result of accu-
mulation of atheromatous plaques in the coronary
arteries, leading to eventual impairment of cardiac blood
flow and potentially devastating consequences of myocar-
dial infarction (MI) or death. CAD is the leading cause of
death in both the United States and worldwide, with over
500,000 deaths per year in the U.S. and over seven mil-
lion worldwide (World Health Organization) [1]. Despite
the development of pharmacologic therapies for preven-
tion, the incidence of CAD is increasing, concomitant
with the rising prevalence of risk factors such as obesity
and diabetes (American Heart Association) [2].
CAD itself is clearly a heritable trait, with the role of
genetic factors becoming increasingly apparent in early-
onset CAD [3-5]. However, the genetic architecture of
CAD, as with many common diseases, is assumed to be
complex and continues to be poorly understood. Candi-
date gene studies have identified several loci for CAD,
but with inconsistent results in validation cohorts.
Recent genome wide association studies (GWAS) have
consistently identified a locus on chromosome 9p21;
however, this locus confers only modest risk of disease
with effect sizes of 1.3-1.6 [6]. Thus, much of the
genetic architecture underlying the heritability of CAD
remains to be elucidated. There are many well-estab-
lished risk factors for CAD that are partitioned between
extrinsic (smoking, sedentary lifestyle, poor nutrition)
and intrinsic (sex, age, lipid levels, hypertension) factors,
each of which may have underlying genetic components,
making it difficult to divide CAD risk into genetic and
non-genetic factors. However, using these intermediate
disease-related intrinsic factors as genetic traits may
help to identify novel CAD genetic loci.
We have previously reported a genome-wide linkage
scan for early-onset CAD using the GENECARD family-
based cohort, which identified nine genomic regions
linked to CAD [7]. The 1q and 3q regions have been
fine-mapped and the susceptibility genes identified
(including FAM5C and KALIRN, respectively) [8,9]. The
signal for 5q31 was present in the overall sample and
was not unique to any one phenotypic subset. However,
using ordered subset analysis (OSA) to dissect genetic
heterogeneity and using lipid levels as quantitative traits,
we found that the evidence for linkage on chromosome
5q was increased in families with higher mean total and
low density lipoprotein-cholesterol (LDL-C) [10].
Rather than focusing on disease status alone as the trait
of interest using one analytic technique, one can apply
multiple methods to CAD and disease-related traits
within one genomic region, thereby exploring the solu-
tion space of the combined analyses and identifying over-
lapping results; such results act as an internal replication
and increase the likelihood that the genetic variant is
truly involved in the pathogenesis of CAD. Recently Wil-
liams and Haines argued that the replication standard is
a strong indicator of a true genetic effect and possibly
preferable to the p-value standard [11].
Thus, we report herein our work to fine-map the CAD
susceptibility locus on chromosome 5q31, using associa-
tion analyses of quantitative (LDL-C) and qualitative
(CAD and atherosclerosis) traits, using the quantitative
results to prioritize the results obtained from qualitative
analyses. We conducted this study in several relatively
large and independent CAD cohorts, including 1908
individuals from a cohort of patients undergoing cardiac
catheterization (CATHGEN), 827 individuals from a
family-based study of early-onset CAD (GENECARD)
and 162 individuals from a repository of aortic tissue
collected from deceased donors. Using this approach of
analyses performed in parallel, we identified four genes
on chromosome 5q31-33 (SPOCK1, PPP2R2B, PRELID2,
and EBF1) as candidate susceptibility genes for CAD
mediated through LDL-C.
Methods
Study populations
All subjects signed a current informed consent form and
these studies were approved by the institutional review
boards of each participating center.
GENECARD family-based study of early-onset CAD
Genetics of Early Onset Cardiovascular Disease (GENE-
CARD) is a multicenter family-based linkage study of
early-onset CAD using an affected sibling pair based
approach; study methods have been described [7]. For
GENECARD, early-onset CAD was defined as: MI or
unstable angina, coronary angiography showing at least
50% stenosis in a major vessel, revascularization proce-
dure as either percutaneous coronary intervention or
coronary artery bypass graft, or a functional test show-
ing reversible myocardial ischemia, occurring before the
age of 51 in men and before the age of 56 in women.
Of the 438 families included in the original linkage
study [7], we selected 254 families, including 726 indivi-
duals (504 affected and 222 unaffected) for analysis of
cardiovascular endpoints. These families were selected
based on the availability of an unaffected family member
to maximize power for association analyses (151
families). In addition, families identified from OSA [10]
that contributed to the linkage peak on chromosome 5
were also included (103 families). For the analysis of
LDL cholesterol traits, 827 individuals from these 254
families were used. LDL-C values were either extracted
from medical records or directly measured using the
Boehringer Manheim cholesterol enzymatic kit (Roche
Diagnostics, Indianapolis, IN, USA) as previously
detailed [10]. Given that LDL-C measurements derived
from medical records were estimated using the
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ide levels greater than 400 mg/dL were coded as missing
for LDL-C. LDL-C measurements greater than four
standard deviations from the mean were coded as miss-
ing in order to exclude undue influences of extreme
outliers.
CATHGEN non-familial cohort
The CATHGEN biorepository consists of sequential
individuals recruited through the cardiac catheterization
laboratory at Duke University Hospital (Durham, NC).
Case-control status in the CATHGEN sample was
assigned as a function of coronary artery disease index
(CADi) and age, such that controls had reached a suffi-
cient age to be at risk of developing disease [9]. All
CATHGEN subjects fasted for a minimum of seven
hours prior to blood sample collection. Blood was col-
lected via the femoral artery and processed immediately
for collection of plasma, and then frozen within hours
at -80°C. For this study, we selected 1908 CATHGEN
subjects based on their CAD status as previously used
for genetic analyses [9]. We had two sources of LDL-C
levels; derived from the medical records for a subset of
the participants; and lipoprotein particle number con-
centration measured in stored, frozen, fasting plasma by
nuclear magnetic resonance spectroscopy through
Liposcience (Liposcience, Raleigh, NC, USA), using pub-
lished techniques [13,14]. For quantitative trait analyses,
total LDL particle number (LDLP) was used as a surro-
gate for LDL-C; in those CATHGEN individuals for
whom both LDL-C and LDLP levels were available (N =
669), the two measures were strongly correlated (r =
0.67, p < 0.0001). Leptin levels were available for 380
individuals from the CATHGEN sample, as previously
reported [10,15]
Human Aorta Tissue Collection
A collection of 162 aortas were harvested from deceased
donors and prepared as previously described [16]. DNA
was extracted from the tissue for genotyping using stan-
dard protocols. In addition, histopathological studies of
the aortas were performed. Specifically, samples were
assessed for extent of early atherosclerotic lesions with
Sudan IV staining and severe disease assessed by the
extent of raised lesions. The burden of atherosclerosis in
the aortas was measured using the protocol described in
the Pathobiological Determinants of Atherosclerosis in
the Young study (PDAY) and were given a graded score
(1-4) [17]. As these aortas were harvested from deceased
donors, the clinical information attached to each sample
was limited, consisting of sex, age, and race.
Laboratory Methods
SNP Selection
SNPs were selected for genotyping based on both the
physical distance between SNPs (density dependent
selection) and based on the pattern of linkage disequili-
brium (LD) within the region (tagging SNPs). SNP map
positions and gene identities were derived from the
most recent draft of the human genome available
(GRCh37/hg19). Within the region of highest lod scores,
the average SNP spacing was 1 per 20 kb. Within the
flanking genomic regions, SNPs were selected for an
average density of 1 per 50 kb. In addition tagging SNPs
were selected to capture LD information within coding
regions using HapMap data and the Tagger algorithm
with the following criteria: an r-squared greater than or
equal to 0.7 and a minor allele frequency (MAF) greater
than or equal to 0.05; LD between SNPs was visualized
using Haploview [18]. One SNP was chosen for each LD
bin. Priority was given to coding SNPs, followed by
SNPs within known regulatory regions, intronic SNPs,
and SNPs located within the 5’ or 3’ UTR, resulting in a
l i s to f7 4 4h a p l o t y p et a g g i n gS N P sw i t ho n eS N Pp e r
LD bin. Finally, any SNPs with an Illumina score of less
than 0.6, a MAF of less than 0.05, or coded as a poten-
tial failure by the Illumina software were excluded from
the selection. The final list contained 2,256 SNPs, com-
posed of both density-dependent (1,512) and tagging
(744) SNPs.
Genotyping
Genomic DNA from the GENECARD and CATHGEN
samples was extracted from whole blood using the Pure-
Gene system (Gentra Systems, Minneapolis, Minnesota,
USA). SNPs were genotyped in two rounds, initially at
the Center for Human Genetics at Duke University and
subsequently through the NHLBI funded Seattle SNPs
(http://pga.gs.washington.edu). The genotyping was per-
formed using the Illumina GoldenGate technology (San
Diego, CA, USA). To ensure genotyping accuracy and
reliability, several quality control methods were used
including two HapMap CEPH individuals and two
duplicate individuals included per 96-well plate. SNPs
with call rates less than 95% (N = 174) were excluded
and individuals with a less than 90% genotyping rate
were excluded (N = 57), resulting in 2082 SNPs on a
total of 2823 individuals available for analysis. Of those,
20 deviated significantly from Hardy-Weinberg equili-
brium (HWE) in Caucasians (p < 0.001) [19]. These 20
SNPs were analyzed, as it has been shown that some
deviations from HWE are consistent with reasonable
models for complex disease [20]. However, none of
these 20 SNPs was significant in any of the analyses per-
formed and had no impact on the reported results.
Statistical Analyses
Association with Quantitative LDL-cholesterol Traits
In the GENECARD sample, association between each
individual SNP with LDL-C was performed using the
quantitative disequilibrium test (QTDT) [21] and a
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average of 122 trios was analyzed per marker (range 30-
196, median 130). In the CATHGEN sample, genotypic
and allelic associations between each individual SNP
and LDLP were assessed using multivariable logistic
regression adjusted for race, age, and sex. Given the low
power for association in the GENECARD study, we
chose to combine the quantitative analysis results for
each SNP from GENECARD and CATHGEN using
Fisher’s method for combining p-values. Given previous
reports that one of our identified genes (EBF1)i sa s s o -
ciated with decreased leptin levels in a murine knockout
model [22], we used the Wilcoxon rank sum test to test
for association of SNPs within and flanking EBF1 with
leptin levels in those CATHGEN individuals with avail-
able leptin data (N = 380).
Association/Linkage Analysis with Cardiovascular Disease
The total SNP panel was tested for association with
CAD in GENECARD and CATHGEN and with athero-
sclerosis in the aorta samples. In the GENECARD study,
parametric two-point linkage for early-onset CAD was
performed with a recessive (at risk allele freq 0.20, and
penetrance 0.001) and dominant (at risk allele freq 0.01,
and penetrance 0.001) model using Vitesse [23] and
Homog [24]. These tests were conducted to provide
independent validation of SNPs showing evidence for
association. In the presence of association and linkage,
there tends to be a positive correlation between tests of
association and linkage; however, there is no such corre-
lation between tests when linkage and association are
not present, implying that true positive results in one
test tend to be reflected by positive results in another
[25]. Family based association with early onset CAD was
performed using the association in the presence of link-
age test (APL) [26]. This test appropriately accounts for
the non-independence of affected siblings and calculates
a robust estimate of the genetic variance.
In the CATHGEN cohort, we used multivariable logis-
tic regression adjusted for race and sex, using allelic and
genotypic models to test for association with CAD case-
control status. In addition, a second CAD case-control
series was constructed using the subset of the GENE-
CARD probands (N = 150) that were sampled from
North America to more closely resemble the CATH-
G E Nc o n t r o l s( N=4 0 0 ) ,a sw eh a v ep r e v i o u s l yd o n e
[9]; in these analyses, logistic regression was used to test
for association between individual SNPs and CAD
adjusted for race and sex.
In the aorta sample, the qualitative phenotype was
atherosclerosis status, defined by a histopathologic index
of atherosclerosis [9], which was analyzed via multivari-
able linear regression, with adjustments for race and sex
under genotypic and allelic models. For all analyses, any
results with a nominal p-value ≤ 0.05 were considered
to be significant. We did not specifically adjust for mul-
tiple comparisons, as our method of comparing multiple
related analyses in independent datasets, which we refer
to as analyses in parallel, provides internal replication
for significant results in the same gene in multiple ana-
lyses and further support the significance of the initial
observation. Analyses were conducted using SAS Ver-
sion 9.1 (Cary, NC) unless otherwise specified for speci-
fic statistical analysis programs (i.e. QTDT, APL and
linkage).
Results
Quantitative Trait Associations for LDL-cholesterol Traits
T h eb a s e l i n ec h a r a c t e r i s t i c so ft h eo v e r a l ls t u d yp o p u l a -
tions have been reported [9]. LDL-C measurements were
available for 827 individuals in the GENECARD cohort,
with a mean LDL-C concentration of 127.1 mg/dL (stan-
dard deviation [SD] 52.3 mg/dL). Family-based associa-
tion resulted in 32 SNPs in 17 distinct genes that were
significantly associated with LDL-C (Additional File 1
Table S1), with the four most significant SNPs residing in
the gene PRELID2 , (PRELI domain containing 2 isoform)
(rs10074645, rs6893183, rs17103583, and rs1865009, p =
0.0002-0.002), which were all in linkage disequilibrium
with each other (D’ ranging from 0.85-0.95). In the
CATHGEN cohort (N = 1,908), mean LDLP levels were
1,131 nmol/L (SD 413 nmol/L). In CATHGEN, we found
102 SNPs in 46 distinct genes that were significantly
associated with LDLP levels (Additional File 2 Table S1),
with the most significant findings for SNPs in the genes
SPOCK1 (sparc/osteonectin, cwcv and kazal-like
domains) (rs17600115, p = 0.003) and PPP2R2B (phos-
phatase 2 regulatory subunitBf a m i l y )( r s 2 1 2 5 4 4 3 ,p=
0.005). Given low power for association in the GENE-
CARD study, the p-values from the GENECARD and
CATHGEN studies were combined using Fisher’s
method, resulting in 51 SNPs with combined p-values ≤
0.05 (Table 1). As such, we found ten genes with signifi-
cant results for association with LDL-C phenotypes in
both the GENECARD and CATHGEN cohorts, with the
strongest, most consistent results for SNPs in PRELID2,
SPOCK1, PPP2R2B,a n dEBF1 (Early B-Cell Factor 1).
The results for the quantitative analyses with LDL-C
traits are summarized in Figure 1.
Given previous studies showing that mouse knockout
models for EBF1 have reduced leptin levels [22], we also
tested all EBF1 SNPs and SNPs upstream and down-
stream of EBF1 (N = 78 SNPs) for association with lep-
tin levels (median 13.8 micrograms/L, range 0.4-104.9
micrograms/L) in a subset of CATHGEN (N = 380); six
EBF1 SNPs were nominally significantly associated with
leptin levels (Additional File 3 Table S1). The most sig-
nificant result was for rs13165442 (p = 0.001), however
that SNP was not significant for association with lipid
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was nominally associated with CAD (p = 0.02) and with
leptin levels (p = 0.03).
Qualitative Trait Association with CAD/atherosclerosis
Those genes with significant results for association with
LDL-C traits were retained for comparison to the CAD
endpoint results; only those genes which had a signifi-
cant result in at least one CAD endpoint were retained
for analysis. This list was further reduced by selecting
those genes with the lowest p-values and the most con-
sistent results across all analyses (i.e. significant results
for the largest number of independent tests).
In the GENECARD sample, 102 SNPs in 45 distinct
genes were significantly associated with CAD using APL
(Additional File 4 Table S1); the most significant results
were SNPs in the genes PPP2R2B (rs7736604, p =
0.0003) and SPOCK1 (rs17170899, p = 0.003). Two-point
linkage analysis in GENECARD resulted in 16 SNPs in
seven genes with LOD scores ≥ 1.5 at θ =0 ,w i t ht h e
highest LOD scores of 2.1 obtained for two SNPs
(rs17166444 in the FSTL4 (follistatin-like 4 precursor)
and rs7736046 in PRELID2) (Additional File 5 Table S1)
and evidence for linkage at both SPOCK1 (rs1919515,
LOD = 1.8) and PRELID2 (rs7736046, LOD = 2.1).
I nt h eC A T H G E Ns a m p l e ,w ef o u n d1 7 8S N P si n5 8
genes that were associated with CAD (Additional File 6
Table S1) with the most significant results for an inter-
genic SNP (rs10050603, p = 0.0002) 628 kb distal to
EBF1. In addition, there were significant results for
PPP2R2B (rs1383169, p = 0.009), PRELID2 (rs7713855,
p = 0.003), SPOCK1 (rs6872714, p = 0.02), and EBF1
(rs6865969, p = 0.007). The GENECARD proband-
CATHGEN case/control validation cohort analysis
resulted in 132 significant SNPs in 60 distinct genes
(Additional File 7 Table S1), with the most significant
evidence for association with CAD for SNPs in ARAP3
(ArfGAP with RhoGAP domain, ankyrin repeat and PH)
(rs6895094, p = 0.0001) and the transcript CTB-99A3.1
(rs11744339, p = 0.0003), which overlaps the genomic
location of PPP2R2B.I na d d i t i o n ,t h eg e n e sEBF1
(rs17712788, p = 0.007), PPP2R2B (rs1383169, p = 0.01),
and SPOCK1 (rs6884385, p = 0.01) also had significant
associations. In the aorta samples, we found 165 SNPs
in 49 genes (Additional File 8 Table S1) that were
Table 1 Association results for chromosome 5q31 SNPs
with LDL-cholesterol traits in the combined GENECARD
and CATHGEN cohorts.
SNP Gene Physical Location (bp) P-value
rs10074645 PRELID2 144965385 0.001
rs1895172 ADAMTS19 128874733 0.002
rs6893183 PRELID2 145018484 0.005
rs1865009 PRELID2 144989633 0.01
rs1460038 intergenic 122077475 0.01
rs32652 TNFAIP8 118705545 0.01
rs11957633 SIL1 138364394 0.01
rs17103583 PRELID2 145044493 0.01
rs17600115 SPOCK1 136420952 0.01
rs7727137 intergenic 122081840 0.01
rs1460039 RP11-166A12.1 122051006 0.01
rs2125443 PPP2R2B 146229428 0.01
rs4921307 ATP10B 160026777 0.02
rs1558095 intergenic 135429640 0.02
rs1558095 intergenic 135429640 0.02
rs728937 intergenic 146485682 0.02
rs7721110 SIL1 138482506 0.02
rs17164449 CTC-228N24.3 127342272 0.02
rs2304052 SPARC 151054227 0.03
rs246869 FAM71B 156584384 0.03
rs44156 intergenic 157625206 0.03
rs6596460 SIL1 138414180 0.03
rs876600 SLC27A6 128235848 0.03
rs6595178 DMXL1 118532034 0.03
rs6863332 intergenic 159234840 0.03
rs962271 ATP10B 160054549 0.03
rs418210 GABRG2 161580983 0.03
rs889010 TRPC7 135572910 0.03
rs367153 ITK 156610846 0.04
rs383915 SLC36A2 150695724 0.04
rs35525 MEGF10 126699347 0.04
rs10875552 PPARGC1B 149189489 0.04
rs12374480 intergenic 154001174 0.04
rs2240793 SLC6A7 149583300 0.04
rs4913054 SH3RF2 145339561 0.04
rs880770 PPARGC1B 149154835 0.04
rs1036199 HAVCR2 156531736 0.04
rs13182800 NR3C1 142801480 0.04
rs12188371 intergenic 117764534 0.04
rs6556615 SGCD 155859368 0.04
rs938537 intergenic 160458036 0.04
rs4244032 NR3C1 142794725 0.04
rs1350375 intergenic 161358888 0.05
rs6595416 SNX24 122268004 0.05
rs1800449 SRFBP1 121413208 0.05
rs2950952 SPOCK1 136654594 0.05
rs193730 intergenic 141154583 0.05
rs162486 intergenic 123073478 0.05
rs586115 FBN2 127662875 0.05
Table 1 Association results for chromosome 5q31 SNPs
with LDL-cholesterol traits in the combined GENECARD
and CATHGEN cohorts. (Continued)
rs17717527 EBF1 158466283 0.05
rs1465689 ARSI 149685855 0.05
The 51 SNPs with p-values ≤0.05 using Fisher’s method for combining results
from CATHGEN and GENECARD are presented.. Results for the four candidate
genes (PPP2R2B, EBF1, SPOCK1, and PRELID2) are in bold.
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sis. The most significant association was with a SNP in
the gene ATPase, class V, type 10B (ATP10B (;
rs1990889, p = 0.001). The genes SPOCK1 (rs2043478, p
= 0.008), PPP2R2B (rs1383167, p = 0.02), and EBF1
(rs6865969, p = 0.02) also contained significantly asso-
ciated SNPs. All of the qualitative results for association
with CAD or degree of atherosclerosis are summarized
in Figure 2.
Analyses in Parallel
Of the 51 SNPs in ten genes that were significantly
associated with LDL-C traits, we further reduced this
list of candidates by selecting only those genes which
had at least one significant association with any of the
CAD endpoints, resulting in a list of nine genes (Figure
3). These genes were then prioritized by both the size of
the p-value and consistency in effect across both quanti-
tative and qualitative analyses. This selection resulted in
a final list of four genes (Table 2) with the most consis-
tent association with LDL-C traits and CAD/athero-
sclerosis, although with varying effects for SNPs within
those genes. The LD pattern for significant SNPs within
each gene showed few examples of strong LD between
significant SNPs (Additional Files 9, 10, 11 and 12), with
the exception of PRELID2 (Additional File 12). In order
to verify the independence of these four loci, pairwise
LD was calculated for all SNPs across the four genes;
there was no LD between SNPs from differing genes
(data not shown).
Discussion
We have demonstrated herein that disease-related inter-
mediate traits can identify novel disease risk genes. Spe-
cifically, we used LDL-cholesterol traits to fine-map a
linkage peak on chromosome 5 from the GENECARD
study of early-onset CAD with integration of these
results with association and linkage to cardiovascular
disease. Using this approach, we have identified four
candidate genes (EBF1, PPP2R2B, PRELID2,a n d
SPOCK1) that may represent novel cardiovascular dis-
ease risk genes mediated through LDL cholesterol
pathways.
Although no genome scans for CAD or MI have
reported linkage to this region, there are several poten-
tially related phenotypes that have been mapped to the
5q31 locus including inflammatory or autoimmune con-
ditions (celiac disease [27], asthma [28], Grave’s disease
[29], psoriasis [30], and Crohn disease [31]) as well as
cardiac and vascular phenotypes (cardiomyopathy [32],
intracranial aneurysm [33], infantile hemangioma [34],
and systolic and diastolic blood pressures [35,36]). Sev-
eral GWAS and meta-analyses have been published for
lipid related traits [37-40]. However, only one study has
Figure 1 Quantitative Associations by Base Pair Position. This figure displays the results of association of SNPs with LDL cholesterol traits in
the GENECARD, CATHGEN and aorta samples, with -log10 of the p-value (Y-axis) versus the base pair position of the SNP (X-axis). The five
candidate genes are labeled with their approximate positions indicated by a horizontal bar.
Nolan et al. BMC Genetics 2012, 13:12
http://www.biomedcentral.com/1471-2156/13/12
Page 6 of 11reported a significant association for any genes on chro-
mosome 5q31-33, for the gene T-cell immunoglobulin
and mucin domain containing 4 (TIMD4) [38], which is
1.7 Mb centromeric to EBF1 and 9.9 Mb telomeric to
PPP2R2B. Nominally significant results were obtained
for SNPs within TIMD4 and its ligand (HAVCR2),
which is 152 kb telomeric to TIMD4 (Additional Files 2
Table S1, 6 Table S1, and 8 Table S1).
Using a database of publicly available GWAS results
from NHGRI, we looked for any reports of significant
associations for SNPs within the 1 lod interval on chro-
mosome 5. There are few references to cardiovascular
disease or disease-related traits. However, none of these
SNPs overlap with significant SNPs in our results, with
the exception of two studies of hypertension/systolic
blood pressure [41,42], each of which reported one sig-
nificant association with a SNP in EBF1; unfortunately,
neither of those two SNPs was examined in our study.
The gene EBF1 is involved in hematopoiesis and
immunity [43]. Interestingly, studies of knockout mice
have identified a role for EBF1 in metabolism [22], a
cardiovascular disease related phenotype. The null mice
described by Fretz et al. have a unique metabolic syn-
drome characterized by lipodystrophy, hypotryglyceride-
mia, and hypoglycemia, while having an increased
metabolic rate and decreased leptin levels. The mouse
lipodystrophy is characterized by an increase in yellow
a d i p o s et i s s u ei nb o n em a r r o wa n dam a r k e dd e c r e a s e
in white adipose tissue (by as much as 90%), relative to
wild type controls. These findings are consistent with
EBF1’s regulation of adipocyte progenitors [44,45]. In
our study, SNPs in EBF1 were significantly associated
with LDL cholesterol traits and the CAD endpoints,
with the exception of two-point linkage. In addition,
EBF1 variation was associated with leptin levels in our
sample, although the results for individual SNPs were
inconsistent with their association with lipids and CAD
endpoints. This may suggest that EBF1 has a similar
role in regulating adiposity and lipid metabolism in
humans, and that variants in the gene may represent
good candidate polymorphisms for cardiovascular dis-
ease and dyslipidemia in humans.
Of the other candidate genes identified, SPOCK1 is
associated with age at menarche via a genome-wide
association study [46,47]. SPOCK1 encodes a proteogly-
can that functions as a protease inhibitor; although initi-
ally identified in testes [48], it is expressed in many
human tissues including blood. SNPs within SPOCK1
were tested for sex-specific effects in our sample via a
stratified analysis; no significant sex effects were
observed (data not shown). PPP2R2B encodes a brain
specific regulatory subunit of a protein phosphatase and
is the causal locus for a Mendelian disease, a form of
spinocerebellar ataxia (SCA12, OMIM# 604326). Little
Figure 2 Qualitative Associations by Base Pair Position. This figure displays the results of association of SNPs with CAD/atherosclerosis in the
GENECARD, CATHGEN and aorta samples, with -log10 of the p-value (Y-axis) versus the base pair position of the SNP (X-axis). The five candidate
genes are labeled with their approximate positions indicated by a horizontal bar; other select genes with significant results are labeled and have
no horizontal bar.
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Page 7 of 11is known about the function of the gene PRELID2 other
than it contains a ‘prel-like domain,’ from which its
name is derived.
Using a strategy of analyses in parallel we have identi-
fied four novel candidate genes for cardiovascular dis-
ease. The ability to reduce the list of potential
candidates within the linkage region on chromosome
5q31-33 from a few hundred to only four is proof of
principle that this strategy may be a useful tool for ana-
lyzing complex traits. In addition, had we relied upon
CAD endpoint analyses alone, we would have obtained
less significant associations overall and would have
prioritized a different set of candidate genes. One of the
major strengths of our study is the detailed phenotype
information available for both the GENECARD cohort
and CATHGEN biorepository. The rigorous inclusion
criteria and case definitions used in GENECARD and
CATHGEN have led to objective measures for CAD
endpoints, a phenotype that would otherwise have a
subjective definition. In this particular study, direct
sequencing, rather than SNP genotyping across multiple
samples, would not have been appropriate; if we were to
re-sequence a sub-set of the sample, it is not clear
which individuals would be selected for such sequen-
cing, particularly for the continuous quantitative traits
we examine. Finally, our sample is of mixed ethnicity
(Caucasian and African-American), which would neces-
sitate a separate re-sequencing effort for each ethnicity.
This study has some limitations. First, all four genes
may be CAD susceptibility genes and act independently
(as the LD patterns in our samples suggest). However, it
is possible that SNPs within our sample are in LD with
causal SNPs at another locus and the association results
from these four genes may not be independent. Second,
we have focused on the consistency of the results at the
gene level (i.e., which genes have SNPs that are signifi-
cant in multiple analyses). However, it is not the case
that the same SNPs are significant in those analyses or,
in the case that the same SNP is significant, that the
magnitude of that significance is similar between ana-
lyses. Thus, we cannot begin to identify individual SNPs
within a candidate gene that are likely to be driving the
results via direct or indirect biological action. This can
be explained, in part, by the fact that the phenotypes,
while correlated, are not perfectly correlated. Therefore,
it is expected that there will be differences in the p-
values for associations with different phenotypes and
this could cause certain associations to fall outside the
nominal p-value cutoff. Finally, the results were not
interpreted in the context of correction for multiple
Figure 3 Analytical Strategy for ‘Parallel Analysis’ of Chromosome 5q31 Region. This figure details the study design, cardiovascular cohorts
and analytic techniques used, and the number of unique genes containing SNPs with significant associations (indicated underneath the method
used). The union of quantitative results (a) indicates the subset of genes shared by the two methods. The qualitative trait (CVD) was analyzed in
GENECARD, CATHGEN, and aortas and the total number of unique genes containing a significant SNP in any of those analyses is indicated. The
commonality of the genes between the quantitative and qualitative analyses (N = 9, PRELID2, SPOCK1, EBF1, PPP2R2B, DMXL1, DTWD2, GABRG2,
GLRA1, and RP11-166A12.1) is indicated by ω.
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Page 8 of 11comparisons. There are two main difficulties with apply-
ing such corrections to these results, i.e. a Bonferroni
correction which would be overly conservative. First, the
phenotypes examined are correlated, therefore the ana-
lyses conducted using more than one phenotype within
t h es a m es a m p l ea r en o ti n d e p e n d e n t .S e c o n d ,i fw e
look at the results sequentially, with one analysis con-
ducted after another, then the prior probability that a
given SNP in a gene of interest will be significant in
subsequent analyses is non-negligible. We are not rely-
ing upon the magnitude of any given p-value to identify
as i n g l eg e n ei nt h er e g i o na st h em o s tl i k e l yt oe x p l a i n
the original evidence for linkage. Rather, we are suggest-
ing that a set of genes be examined as likely candidate
susceptibility loci for cardiovascular disease that is
mediated by lipid levels.
In order to identify which gene or genes among the
four we have selected contains variation for cardiovascu-
lar disease mediated by LDL cholesterol pathways, there
are several methodologies available. Re-sequencing stu-
dies could be conducted in our sample, either in the
entire population or by using individuals with extreme
trait values (i.e., very high/low LDL-C levels or very
early onset cardiovascular disease), as these data would
capture all of the variation present in those samples and
not rely upon common variants identified through a dif-
ferent, although ethnically similar, sample (i.e., CEPH
Caucasians). In addition, those genes for which the bio-
logical function is known (i.e., EBF1)c o u l dh a v et h e i r
level of activity or functionality directly assessed in gen-
otyped samples. Such an approach can identify subsets
of variation that appear to have functional conse-
quences. However, due to LD within the variants, such
results can still be ambiguous, in which case promoter
and gene constructs can be created and assayed in the
laboratory, allowing one to query the functional conse-
quences of individual variants
Conclusions
In summary, we propose a strategy of parallel analysis
where results from analyses of disease-related intermedi-
ate traits for a complex disease can be considered jointly
with qualitative results from mapping of the disease trait
itself, potentially enabling discovery of novel disease
genes mediated through these intermediate phenotypes
that might not have been identified using disease status
Table 2 Summary of results across cohorts for four candidate genes identified through parallel analysis.
Gene SNP Quantitative Results Qualitative Results
(LDL Cholesterol Traits) (CAD, Atherosclerosis)
LDL-
GENECARD
LDLP-
CATHGEN
Fisher’s
Combined
GENECARD CATHGEN GENECARD Probands-
CATHGEN Controls
Aortas Linkage
(LOD)
PPP2R2B rs10037715 0.05 0.77 0.15 0.82 0.31 0.25 0.68 -17.8
rs2125443 0.38 0.001 0.01 0.71 0.31 0.84 0.13 -14.4
rs7736604 0.92 0.01 0.06 0.0003 0.22 0.45 0.02 -13.2
rs160974 0.92 0.62 0.62 0.47 0.004 0.50 0.65 -18.0
rs1383169 0.81 0.11 0.31 0.39 0.01 0.01 0.49 -9.3
rs1383167 0.99 0.28 0.63 0.45 0.08 0.92 0.02 -14.2
EBF1 rs17717527 0.01 0.73 0.05 0.40 0.55 0.13 0.31 -19.5
rs6865969 0.84 0.01 0.05 0.40 0.01 0.13 0.02 -20.0
rs4704963 0.78 0.24 0.51 0.03 0.67 0.38 0.46 -6.4
rs17712788 0.08 0.90 0.90 0.85 0.33 0.01 0.16 -8.3
SPOCK1 rs10054991 0.05 0.84 0.17 0.72 0.79 0.14 0.33 -14.8
rs17600115 0.33 0.003 0.001 0.85 0.27 0.43 0.05 -5.7
rs17170899 0.71 0.98 0.95 0.004 0.63 0.82 0.86 -1.6
rs6872714 0.19 0.80 0.44 0.91 0.02 0.64 0.04 -16.8
rs6884385 0.16 0.17 0.13 0.86 0.06 0.02 0.24 -16.0
rs2043478 0.88 0.77 0.94 0.49 0.33 0.23 0.01 -17.3
rs1919515 0.80 0.59 0.82 0.42 0.74 0.05 0.36 1.8
PRELID2 rs10074645 0.0002 0.71 0.001 0.93 0.67 0.19 0.66 -2.7
rs11950106 0.73 0.04 0.12 0.56 0.09 0.30 0.73 -13.7
rs7713855 0.93 0.54 0.85 0.77 0.003 0.13 0.33 -16.2
rs13179436 0.65 0.77 0.85 0.52 0.005 0.03 0.26 -16.0
rs443033 0.50 0.90 0.81 0.48 0.05 0.14 0.04 -10.1
rs7736046 0.98 0.80 0.98 0.86 0.03 0.81 0.19 2.1
P-values for the most significant results for SNPs for each analysis for the four top candidate genes (PPP2R2B, EBF1, SPOCK1, and PRELID2) are presented. The
most significant result for each gene and analysis is in bold.
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Page 9 of 11alone. In addition, this strategy may allow the dissection
of genetic heterogeneity mediated through the inter-
mediate phenotype. We have applied this strategy to the
fine mapping of a linkage peak for early-onset CAD and
thereby have demonstrated replication of four genes
within a region on chromosome 5q31. These genes, in
particular, EBF1 given its potential biological plausibility,
serve as novel candidate loci for cardiovascular disease
and should be further evaluated.
Additional material
Additional file 1: Genes associated with LDL cholesterol traits in the
GENECARD study. This table displays minor allele frequencies (MAF),
sample sizes, and p-values for the most significant SNPs associated with
LDL cholesterol using the quantitative trait disequilibrium test (QTDT) in
the GENECARD study. Note that the sample size is less than the overall
GENECARD study sample size since not all families could be included
due to lack of unaffecteds. SNPs within our four key candidate genes are
in bold.
Additional file 2: Genes associated with LDL cholesterol traits in the
CATHGEN cohort. Displayed are the results for association of SNPs with
LDLP levels in the CATHGEN sample. The significant SNPs are shown
followed by the genic location, base pair position, and the
corresponding p-value. SNPs within our four key candidate genes are
presented in bold.
Additional file 3: Associations of EBF1 SNPs with Leptin Levels. Six
SNPs within and flanking EBF1 are listed with their Wilcoxon rank test p-
values for association with leptin levels in CATHGEN in the total sample
with available leptin levels, and stratified by race.
Additional file 4: Association of SNPs with CAD in the GENECARD
cohort. Displayed are results of the qualitative analysis using APL in the
GENECARD sample. All significant SNPs are shown followed by their
genic location, base pair position, and their corresponding p-values.
Results within our four key candidate genes are displayed in bold.
Additional file 5: Linkage results for SNPs with early-onset CAD in
the GENECARD cohort. Displayed are linkage results for the GENECARD
sample. All SNPs with two-point lod scores ≥ 1.5 are listed followed by
their genic location, base pair position, individual lod score, and genetic
model used.
Additional file 6: Association of SNPs with CAD in the CATHGEN
Cohort. Displayed are all significant results for the case-control analysis
of SNPs with CAD in the CATHGEN sample. Each significant SNP is listed
followed by their genic location, base pair, p-value, odds ratio, and 95%
confidence interval for the genotypic and allelic models, respectively.
Additional file 7: Association of SNPs with CAD for GENECARD
proband vs. CATHGEN controls sample set. Displayed are the results
of the GENECARD proband-CATHGEN control analysis, with all significant
SNPs listed followed by their genic location, base pair position, p-value,
odds ratio, and 95% confidence intervals for the genotypic and allelic
models used.
Additional file 8: Association of SNPs with Degree of
Atherosclerosis in the Aorta Samples. Displayed are results of
association of SNPs with degree of atherosclerosis in the aorta samples,
with each significant SNP listed followed by their genic position, base
pair position, p-value, odds ratio, and 95% confidence interval for the
genotypic and allelic models.
Additional file 9: Linkage disequilibrium patterns of select SNPs in
PPP2R2B. LD pattern using Haploview, with r-squared values displayed
within each box and the shading of the boxes corresponding do D’
values.
Additional file 10: Linkage disequilibrium patterns of select SNPs in
EBF1. LD pattern using Haploview, with r-squared values displayed
within each box and the shading of the boxes corresponding do D’
values.
Additional file 11: Linkage disequilibrium patterns of select SNPs in
SPOCK1. LD pattern using Haploview, with r-squared values displayed
within each box and the shading of the boxes corresponding do D’
values.
Additional file 12: Linkage disequilibrium patterns of select SNPs in
PRELID2. LD pattern using Haploview, with r-squared values displayed
within each box and the shading of the boxes corresponding do D’
values.
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